Literature DB >> 15845415

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.

Elaine M Leslie1, Roger G Deeley, Susan P C Cole.   

Abstract

In tumor cell lines, multidrug resistance is often associated with an ATP-dependent decrease in cellular drug accumulation which is attributed to the overexpression of certain ATP-binding cassette (ABC) transporter proteins. ABC proteins that confer drug resistance include (but are not limited to) P-glycoprotein (gene symbol ABCB1), the multidrug resistance protein 1 (MRP1, gene symbol ABCC1), MRP2 (gene symbol ABCC2), and the breast cancer resistance protein (BCRP, gene symbol ABCG2). In addition to their role in drug resistance, there is substantial evidence that these efflux pumps have overlapping functions in tissue defense. Collectively, these proteins are capable of transporting a vast and chemically diverse array of toxicants including bulky lipophilic cationic, anionic, and neutrally charged drugs and toxins as well as conjugated organic anions that encompass dietary and environmental carcinogens, pesticides, metals, metalloids, and lipid peroxidation products. P-glycoprotein, MRP1, MRP2, and BCRP/ABCG2 are expressed in tissues important for absorption (e.g., lung and gut) and metabolism and elimination (liver and kidney). In addition, these transporters have an important role in maintaining the barrier function of sanctuary site tissues (e.g., blood-brain barrier, blood-cerebral spinal fluid barrier, blood-testis barrier and the maternal-fetal barrier or placenta). Thus, these ABC transporters are increasingly recognized for their ability to modulate the absorption, distribution, metabolism, excretion, and toxicity of xenobiotics. In this review, the role of these four ABC transporter proteins in protecting tissues from a variety of toxicants is discussed. Species variations in substrate specificity and tissue distribution of these transporters are also addressed since these properties have implications for in vivo models of toxicity used for drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845415     DOI: 10.1016/j.taap.2004.10.012

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  319 in total

1.  Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae.

Authors:  Chenrui Li; Li Zhang; Limin Zhou; Siu Kwan Wo; Ge Lin; Zhong Zuo
Journal:  AAPS J       Date:  2011-12-14       Impact factor: 4.009

Review 2.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 3.  Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit.

Authors:  Hitoshi Ishimoto; Robert B Jaffe
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

4.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

Review 5.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

6.  A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Authors:  Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

Review 7.  ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

Authors:  Saroj Velamakanni; Shen L Wei; Tavan Janvilisri; Hendrik W van Veen
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

8.  ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.

Authors:  Hoang Dinh Tuy; Hisanori Shiomi; Ken Ichi Mukaisho; Shigeyuki Naka; Tomoharu Shimizu; Hiromichi Sonoda; Eiji Mekata; Yoshihiro Endo; Yoshimasa Kurumi; Hiroyuki Sugihara; Masaji Tani; Tohru Tani
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

9.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

10.  Methylation of SFRP5 is related to multidrug resistance in leukemia cells.

Authors:  H Wang; X Wang; R Hu; W Yang; A Liao; C Zhao; J Zhang; Z Liu
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.